KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Enterprise Value: 2011-2025

Historic Enterprise Value for Sarepta Therapeutics (SRPT) over the last 15 years, with Sep 2025 value amounting to $1.0 billion.

  • Sarepta Therapeutics' Enterprise Value fell 90.37% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.2 billion, marking a year-over-year decrease of 141.60%. This contributed to the annual value of $10.3 billion for FY2024, which is 60.28% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Enterprise Value of $1.0 billion as of Q3 2025, which was up 43.80% from $717.6 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Enterprise Value registered a high of $13.5 billion during Q2 2024, and its lowest value of $717.6 million during Q2 2025.
  • Its 3-year average for Enterprise Value is $7.9 billion, with a median of $9.6 billion in 2023.
  • As far as peak fluctuations go, Sarepta Therapeutics' Enterprise Value spiked by 113.66% in 2023, and later slumped by 94.67% in 2025.
  • Over the past 5 years, Sarepta Therapeutics' Enterprise Value (Quarterly) stood at $5.7 billion in 2021, then spiked by 63.93% to $9.4 billion in 2022, then tumbled by 31.80% to $6.4 billion in 2023, then skyrocketed by 60.28% to $10.3 billion in 2024, then slumped by 90.37% to $1.0 billion in 2025.
  • Its Enterprise Value was $1.0 billion in Q3 2025, compared to $717.6 million in Q2 2025 and $5.3 billion in Q1 2025.